Metastatic melanoma clinical trial results to be presented at major meeting

Results from a metastatic melanoma clinical trial will be presented at a major melanoma conference in Sydney next month.

The Phase 2 study has been testing an experimental drug called PV-10 which has been developed by Provectus Pharmaceuticals.

The results will include data on progression-free survival and overall survival. They are based on observation of the clinical trial’s full population of 80 participants.

The metastatic melanoma presentation is being made at the 7th International Melanoma Research Congress. The event – which organisers say will be one of the decade’s most important global gatherings of melanoma experts - is being held between 4-7 November 2010.

The scale of the Congress is down to the fact that it will bring together four major meetings:
•    7th International Congress of the Society for Melanoma Research.
•    4th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres.
•    3rd Melanoma Pathology Symposium of the International Melanoma Pathology Working Group.
•    Melanoma Update for Primary Care Clinicians

Although each meeting will have a unique focus, there will be significant – and deliberate – overlap.

The Society for Melanoma Research meeting will allow researchers and clinicians to focus on biology and treatment.

Meanwhile, the Interdisciplinary Melanoma/Skin Cancer Centres meeting will address the objectives defined for the inaugural 2007 meeting in Barcelona. These are:
•    To consider the current optimal clinical care for patients
•    The opportunities provided by highly integrated interdisciplinary care and research
•    Facilitate the development of the infrastructure and systems to undertake these activities.

The Melanoma Pathology Symposium will highlight key issues in pathology, clinical care and research.

Finally, the Melanoma Update for Primary Care Clinicians will offer comprehensive clinical care reviews of diagnostics, surgery and medical oncology.